Skip to main content

FDA Approvals

FDA Approvals
Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Loretta Fala
Read More
FDA Approvals
Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes
Mary Mosley
Read More
FDA Approvals
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Read More
FDA Approvals
GLP-1 Agonists May Protect Patients with Diabetes from Heart Failure
Wayne Kuznar
Read More
FDA Approvals
Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Read More
FDA Approvals
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Read More
FDA Approvals
SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance
Wayne Kuznar
Read More
FDA Approvals
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Read More
FDA Approvals
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Read More
Page 46 of 53
Results 451 - 460 of 525